Fast Five Quiz: Severe Asthma Phenotypes

Zab Mosenifar, MD

Disclosures

April 05, 2021

Together with blood/sputum eosinophil count, high FeNO may be a biomarker for the late-onset severe asthma phenotype. Clinical characteristics of this phenotype may include chronic rhinosinusitis with nasal polyps and/or steroid refractoriness.

The AERD phenotype is also typically severe from onset, with frequent exacerbations. In such patients, helpful biomarkers for identification include blood/sputum eosinophil count and urinary leukotriene E4 (LTE4).

Serum IL-6 is a biomarker that may be seen in the obese asthma phenotype.

Induced sputum neutrophil count is another biomarker than can help to identify asthma phenotypes. Recently, association of neutrophilic airway inflammation with severe asthma has been shown in the context of non–type 2 inflammation, which may or may not be accompanied by type 2 inflammation and airway eosinophils.

For additional information, refer to the Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention.

Learn more about combination therapy in the management of patients with severe asthma.

Editor's Recommendations

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....